USANA Health Sciences, Inc. (NYSE:USNA) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its position in shares of USANA Health Sciences, Inc. (NYSE:USNA - Free Report) by 5.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,090,864 shares of the company's stock after selling 58,400 shares during the period. Renaissance Technologies LLC owned about 5.72% of USANA Health Sciences worth $39,151,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the business. Centiva Capital LP acquired a new position in USANA Health Sciences in the third quarter worth approximately $213,000. State Street Corp grew its position in USANA Health Sciences by 0.6% during the third quarter. State Street Corp now owns 435,164 shares of the company's stock worth $16,501,000 after buying an additional 2,782 shares in the last quarter. Barclays PLC lifted its holdings in shares of USANA Health Sciences by 111.9% during the 3rd quarter. Barclays PLC now owns 27,737 shares of the company's stock worth $1,052,000 after acquiring an additional 14,647 shares during the period. Geode Capital Management LLC boosted its stake in shares of USANA Health Sciences by 4.5% in the 3rd quarter. Geode Capital Management LLC now owns 297,120 shares of the company's stock valued at $11,269,000 after purchasing an additional 12,898 shares in the last quarter. Finally, Franklin Resources Inc. grew its holdings in shares of USANA Health Sciences by 9.2% during the third quarter. Franklin Resources Inc. now owns 21,050 shares of the company's stock worth $750,000 after purchasing an additional 1,771 shares during the last quarter. Institutional investors own 54.25% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on USNA shares. StockNews.com downgraded shares of USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a report on Tuesday, February 18th. Finally, DA Davidson reduced their price objective on shares of USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating on the stock in a research note on Thursday, February 27th.

Insiders Place Their Bets

In related news, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the sale, the chief executive officer now owns 15,716 shares of the company's stock, valued at approximately $463,150.52. This represents a 24.14 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David Mulham Mulham sold 3,234 shares of the stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $32.98, for a total transaction of $106,657.32. Following the transaction, the insider now directly owns 12,775 shares of the company's stock, valued at approximately $421,319.50. This trade represents a 20.20 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 15,920 shares of company stock worth $500,285. 0.33% of the stock is currently owned by company insiders.

USANA Health Sciences Price Performance

NYSE USNA traded down $0.44 during trading on Wednesday, reaching $23.57. The company's stock had a trading volume of 34,152 shares, compared to its average volume of 116,682. The stock has a market capitalization of $445.59 million, a PE ratio of 8.33, a P/E/G ratio of 0.93 and a beta of 1.00. The firm has a fifty day moving average of $28.88 and a 200 day moving average of $33.83. USANA Health Sciences, Inc. has a one year low of $23.54 and a one year high of $49.78.

USANA Health Sciences (NYSE:USNA - Get Free Report) last posted its earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, beating analysts' consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. The company had revenue of $213.61 million for the quarter, compared to the consensus estimate of $208.82 million. Research analysts expect that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.